Amgen Inc (AMGN)
$306.92 -4.63 (-1.49%)Market Cap | 167.37B |
Revenue (ttm) | 33.42B |
Net Income (ttm) | 4.09B |
EPS (ttm) | N/A |
PE Ratio | 15.49 |
Forward PE | 14.88 |
Profit Margin | 12.24% |
Debt to Equity Ratio | 10.23 |
Volume | 3,041,200 |
Avg Vol | 3,145,540 |
Day's Range | N/A - N/A |
Shares Out | 537.21M |
Stochastic %K | 52% |
Beta | 0.53 |
Analysts | Sell |
Price Target | $319.04 |
Latest News on AMGN




Mar 26, 2025, 1:37 PM EDT - 6 days ago
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity



Mar 8, 2025, 6:00 AM EST - 24 days ago
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Mar 7, 2025, 10:58 AM EST - 25 days ago
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket

Mar 5, 2025, 11:09 AM EST - 27 days ago
Amgen Inc. (AMGN) 45th Annual TD Cowen Health Care Conference (Transcript)

Mar 5, 2025, 9:54 AM EST - 27 days ago
Amgen starts two critical late-stage trials for weight loss drug MariTide


Mar 1, 2025, 5:30 PM EST - 4 weeks ago
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Feb 28, 2025, 4:01 PM EST - 4 weeks ago
AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Feb 27, 2025, 1:53 PM EST - 4 weeks ago
Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG


Feb 19, 2025, 10:46 PM EST - 5 weeks ago
Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)

Feb 14, 2025, 4:01 PM EST - 6 weeks ago
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

Feb 12, 2025, 3:22 PM EST - 6 weeks ago
Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript


Feb 7, 2025, 4:01 PM EST - 7 weeks ago
AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE


Feb 6, 2025, 7:37 AM EST - 7 weeks ago
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)

Feb 5, 2025, 3:08 PM EST - 7 weeks ago
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating

Feb 5, 2025, 12:21 PM EST - 7 weeks ago
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead

Feb 4, 2025, 4:31 PM EST - 2 months ago
Amgen shares sink despite quarterly beat, FDA places obesity drug on clinical hold

Feb 4, 2025, 4:06 PM EST - 2 months ago
Amgen profit beats estimates, next MariTide studies start by mid-year

Feb 4, 2025, 4:01 PM EST - 2 months ago
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Jan 31, 2025, 6:30 PM EST - 2 months ago
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS


Jan 17, 2025, 9:01 AM EST - 2 months ago
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Jan 13, 2025, 8:36 PM EST - 2 months ago
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)


Jan 8, 2025, 4:01 PM EST - 2 months ago
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE